StockrabitBrowse analysts
Analyst questions

Rishikesh Patole

Batlivala & Karani Securities
NATCOPHARM

Natco Pharma Limited

All company calls
Natco Pharma Limited CC-Sep23.pdf
15 Nov 2023
Open call
  1. So, just last year, same quarter, was pure base business with out revenue and even without the aggregate scale-up and we had reported margins in the range of around 22%. So, is that the right way to look at the business ex-of revenue?

    Read in transcript
  2. Just to -- what was the R&D number for 2Q, this year?

    Read in transcript
  3. And that would be the same trend going ahead?

    Read in transcript
+1 more question in this call